The previously accepted division of clinical mycoses into superficial, subcutaneous and systemic was an extremely artificial one, since, when the conditions are favourable, every fungus is able to grow either on or under the skin. However the treatment of systemic mycoses differs fundamentally from the treatment of the mycoses developed on the skin surface. Only for these latter conditions is the use of topical agents effective.
Mycoses must be divided in two groups according to their etiology: the true mycoses, which are the subject of this meeting, and the diseases produced by the actinomyces. The treatment of these 'pseudomycoses' such as actinomycosis or nocardiosis, depends on sulphonamides and antibacterial antibiotics (Vanbreuseghem 1966) . Since the actinomyces are bacteria, the treatment of such pseudomycoses is that adopted for bacterial diseases and for that reason it is very much in advance on the treatment of the true mycoses such as candidosis, aspergillosis and cryptococcosis. This latter problem is far from being solved. Though some progress has been made, it is comparatively little.
Potassium iodide has for a long time been considered as a panacea. It is active in 100% of the conventional types of sporotrichosis, and it has been used with some success in basidiobolomycosis and entomophthorosis.
As soon as sulphonamides were introduced into antibacterial therapy they also found their place in the treatment of the South-American blastomycosis. I believe that they are still used, as we will learn later.
The first antifungal antibiotic was isolated by Paul Simonart from Louvain, during his work on Penicillium griseofulvum in the laboratories of Oxford and Raistrick in England (Oxford et al. 1939) . But it had to wait for the work of Gentles (1958) to find its use in medicine. This was one of the first antibiotics active in systemic mycoses if they are caused by a dermatophyte such as in 'la maladie dermatophytique' (Hadida & Schousboe 1959) , or in dermatophytic mycotoma. In addition it is a major treatment for ringworm of all sorts.
However we have few forms of treatment for the largest number of mycoses, those caused by normal pathogens or those produced by the socalled opportunistic fungi in the compromised host. Vanbreuseghem & Larsh (1976) proposed Professor R Vanbreuseghem to call these asthenomycoses because they develop in hosts who show very little resistance.
With regard to amphotericin B, I used to teach that it kills as many patients as it cures, although it remains one of the most reliable antifungal drugs in our possession. Its recent use in combination with other drugs has shown that it acts synergistically with fluorocytosine, rifampicin or tetracyclines in penetrating the fungal cell by breaking the cell wall barrier. However, it can also enhance the toxicity ofsome drugs. According to Medoff & Kobayashi (1975) the future of amphotericin B lies in the correct adjustment of its dosage together with the choice of a correct partner to elicit the best immunological response and avoid unwanted toxicity. 5-fluorocytosine (or flucytosine) did at first appear to be a good drug against cryptoce -cus, candida, torulopsis and some other fungi. In contrast with amphotericin B it is easily absorbed by the intestinal tract, it gets to the brain easily and is not toxic except in case of kidney failure. According to Harder & Hermans (1975) , however, it produces a mild leukopenia, a mild thrombocytopenia, an increase in alkaline phosphatase and glutamic oxaloacetic transaminase, some nausea and diarrhoea.
But flucytosine induces resistance to cryptococcus to such a point that Krick & Remington (1975) severely criticizing the paper of Harder & Hermans (1975) did not recommend the use of flucytosine alone for the treatment of cryptococcal meningitis. They adopted the same careful attitude for the treatment of systemic candidosis or of urinary candidosis, remarking that in combination with amphotericin B, its renal toxicity is much increased.
What we need is a safe, broad-spectrum antibiotic or antifungal drug which produces no resistance, which is active and which is well tolerated by an organism whose resistance is already often lowered by the primary disease or by the treatment.
Have we found it in miconazole? I have read most of the papers to be presented today. Some are very good. Others are less convincing, but all are very promising.
Those people testing antifungal drugs should be very careful in deciding the exact pathological status of their patient. It is now appreciated that candidxemia and disseminated candidosis are not synonyms, that the first is often absent when the second is well developed and that candidxemia does not necessarily lead to systemic candidosis.
Candiduria has greater significance than candidemia if it can be proved that it was not the result of an infection through the urethral route. If this can be eliminated, every effort has to be made to diagnose systemic candidosis.
Similarly C. neoformans is more and more frequently isolated from the sputum in patients with chronic respiratory disease and it is accepted that lung biopsy proving the presence of the yeast in the tissues is the only correct technique to establish the existence of pulmonary cryptococcosis. But it is also admitted that this disease may resolve spontaneously (Hook & Maser 1965) .
Aspergillus in the sputum has no meaning if it cannot be associated with other proofs such as precipitin tests or lung biopsies. Krick & Remington (1975) , however, admit that in a compromised host with leukemia or following transplantation the presence of aspergillus in the sputum is an indication for amphotericin therapy.
With these remarks in mind let us face the day. I am convinced that this symposium will have all the success it deserves. Summary A classification of mycoses, depending upon the depth of penetration of the organism is discussed, as is the need to distinguish the true from the 'pseudo' mycoses. The development of antifungal agents is described from the first antibiotics to amphotericin B and 5-fluorocytosine. Attention is particularly focussed on the question of safety and effectiveness.
Finally, it is stressed that successful antifungal treatment must depend upon determination of the exact pathological status of the patient and examples are given which relate to such clinical assessments.
